Exploring the Successes and Failures of Inhaled Surfactant in the Utility of Current Surfactant Aerosol Delivery Systems
Time: 3:30 pm
day: Day 2
Details:
- With the exception of FDA approvals for surfactant delivery for pre-term infants and neonates, this therapeutic modality has not delivered consistent results in the management of surfactant deficiency conditions
- Addressing barriers: what has hindered the addition of surfactant delivery to the therapeutic armamentarium?
- Enhancing aerosol delivery: what enhancements are needed to make surfactant a valuable treatment across various diseases like ARDS and COPD?
